The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
But this week three transactions did squeak through.
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.